Q32 Bio Reports Q2 Results, Cash Runway Through Phase 3, and Plans for Bempikibart Registration Trial in 2027
QTTB has more than doubled off its 52-week low of $1.569.
Summary
Q32 Bio reported Q2 2026 financials with $106.3M in cash as of June 30, which combined with the July $200M offering extends runway through Phase 3 topline results for bempikibart. The company plans to initiate a registration-directed trial in severe alopecia areata in H1 2027, pending regulatory discussions later this year. This follows the positive Phase 2a data in July that showed a 35.3% mean SALT reduction. Additional 36-week and initial 52-week data will be presented at a medical conference in H2 2026. The update confirms the company is capitalized to reach the next major clinical milestone, reducing near-term financing risk.
At the time of this announcement, QTTB was trading at $16.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $480.8M. The 52-week trading range was $1.57 to $23.57. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.